Discovering personalized driver mutation profiles of single samples in cancer by network control strategy

Motivation It is a challenging task to discover personalized driver genes that provide crucial information on disease risk and drug sensitivity for individual patients. However, few methods have been proposed to identify the personalized-sample driver genes from the cancer omics data due to the lack of samples for each individual. To circumvent this problem, here we present a novel single-sample controller strategy (SCS) to identify personalized driver mutation profiles from network controllability perspective. Results SCS integrates mutation data and expression data into a reference molecular network for each patient to obtain the driver mutation profiles in a personalized-sample manner. This is the first such a computational framework, to bridge the personalized driver mutation discovery problem and the structural network controllability problem. The key idea of SCS is to detect those mutated genes which can achieve the transition from the normal state to the disease state based on each individual omics data from network controllability perspective. We widely validate the driver mutation profiles of our SCS from three aspects: (i) the improved precision for the predicted driver genes in the population compared with other driver-focus methods; (ii) the effectiveness for discovering the personalized driver genes and (iii) the application to the risk assessment through the integration of the driver mutation signature and expression data, respectively, across the five distinct benchmarks from The Cancer Genome Atlas. In conclusion, our SCS makes efficient and robust personalized driver mutation profiles predictions, opening new avenues in personalized medicine and targeted cancer therapy. Availability and implementation The MATLAB-package for our SCS is freely available from http://sysbio.sibcb.ac.cn/cb/chenlab/software.htm. Contact zhangsw@nwpu.edu.cn or zengtao@sibs.ac.cn or lnchen@sibs.ac.cn. Supplementary information Supplementary data are available at Bioinformatics online.

[1]  A. Vinayagam,et al.  A Directed Protein Interaction Network for Investigating Intracellular Signal Transduction , 2011, Science Signaling.

[2]  Jagdish Chandra Patra,et al.  Genome-wide inferring gene-phenotype relationship by walking on the heterogeneous network , 2010, Bioinform..

[3]  Jian Peng,et al.  A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information , 2017, Nature Communications.

[4]  H. Hollema,et al.  The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer , 2008, British Journal of Cancer.

[5]  Susumu Goto,et al.  Data, information, knowledge and principle: back to metabolism in KEGG , 2013, Nucleic Acids Res..

[6]  G. Nemhauser,et al.  Integer Programming , 2020 .

[7]  J. P. Hou,et al.  DawnRank: discovering personalized driver genes in cancer , 2014, Genome Medicine.

[8]  Benjamin J. Raphael,et al.  De novo discovery of mutated driver pathways in cancer , 2011 .

[9]  Ching-tai Lin.  Structural controllability , 1974 .

[10]  Allan R. Jones,et al.  Comprehensive transcriptional map of primate brain development , 2016, Nature.

[11]  Juan Liu,et al.  Transittability of complex networks and its applications to regulatory biomolecular networks , 2014, Scientific Reports.

[12]  Peilin Jia,et al.  VarWalker: Personalized Mutation Network Analysis of Putative Cancer Genes from Next-Generation Sequencing Data , 2014, PLoS Comput. Biol..

[13]  Léon Personnaz,et al.  Enrichment or depletion of a GO category within a class of genes: which test? , 2007, Bioinform..

[14]  Xiangtian Yu,et al.  Big-data-based edge biomarkers: study on dynamical drug sensitivity and resistance in individuals , 2016, Briefings Bioinform..

[15]  D. Haber,et al.  Cancer: Drivers and passengers , 2007, Nature.

[16]  Juan Liu,et al.  Pattern fusion analysis by adaptive alignment of multiple heterogeneous omics data , 2017, Bioinform..

[17]  K. Aihara,et al.  Personalized characterization of diseases using sample-specific networks , 2016, bioRxiv.

[18]  Yee Lian Chew,et al.  Network control principles predict neuron function in the Caenorhabditis elegans connectome , 2017, Nature.

[19]  Stephen T. C. Wong,et al.  Optimal Drug Prediction From Personal Genomics Profiles , 2015, IEEE Journal of Biomedical and Health Informatics.

[20]  Andrew M. Gross,et al.  Network-based stratification of tumor mutations , 2013, Nature Methods.

[21]  Weiguo Lu,et al.  Ovarian carcinoma cells inhibit T cell proliferation: suppression of IL-2 receptor β and γ expression and their JAK-STAT signaling pathway , 2004 .

[22]  C. Sander,et al.  Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.

[23]  Stephen T. C. Wong,et al.  A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles , 2015, BMC Genomics.

[24]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[25]  David Bernstein,et al.  Impaired IRS‐1/PI3‐kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes , 2003, Hepatology.

[26]  Laurence A. Wolsey,et al.  Integer and Combinatorial Optimization , 1988, Wiley interscience series in discrete mathematics and optimization.

[27]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[28]  Laurence A. Wolsey,et al.  Integer and Combinatorial Optimization , 1988 .

[29]  George Kollias,et al.  The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. , 2009, The Journal of clinical investigation.

[30]  L. Serrano,et al.  Engineering stability in gene networks by autoregulation , 2000, Nature.

[31]  Benjamin J. Raphael,et al.  Network propagation: a universal amplifier of genetic associations , 2017, Nature Reviews Genetics.

[32]  Lincoln Stein,et al.  Reactome: a database of reactions, pathways and biological processes , 2010, Nucleic Acids Res..

[33]  Albert-László Barabási,et al.  Target control of complex networks , 2014, Nature Communications.

[34]  G. Mills,et al.  CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features , 2013, PloS one.

[35]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[36]  S Joshua Swamidass,et al.  Unsupervised detection of cancer driver mutations with parsimony-guided learning , 2016, Nature Genetics.

[37]  Zhuowen Tu,et al.  Similarity network fusion for aggregating data types on a genomic scale , 2014, Nature Methods.

[38]  A. Bashashati,et al.  DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer , 2012, Genome Biology.

[39]  Albert-László Barabási,et al.  Controllability of complex networks , 2011, Nature.

[40]  Kern Rei Chng,et al.  Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles , 2015, Nucleic acids research.

[41]  Setia Pramana,et al.  Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival , 2015, Bioinform..

[42]  Susumu Goto,et al.  KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..

[43]  Yufei Huang,et al.  m6A-Driver: Identifying Context-Specific mRNA m6A Methylation-Driven Gene Interaction Networks , 2016, PLoS Comput. Biol..

[44]  Paul S Mischel,et al.  Targeted Molecular Therapy of GBM , 2003, Brain pathology.

[45]  Kazuyuki Aihara,et al.  Detecting early-warning signals for sudden deterioration of complex diseases by dynamical network biomarkers , 2012, Scientific Reports.

[46]  L. Stein,et al.  A human functional protein interaction network and its application to cancer data analysis , 2010, Genome Biology.

[47]  R. Bernards,et al.  Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.

[48]  Susmita Datta,et al.  Finding common genes in multiple cancer types through meta-analysis of microarray experiments: a rank aggregation approach. , 2008, Genomics.

[49]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[50]  D. House,et al.  Ozone-induced inflammation in the lower airways of human subjects. , 1989, The American review of respiratory disease.

[51]  S. Armstrong,et al.  FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress , 2007, Cell.

[52]  Leyla Isik,et al.  Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. , 2009, Cancer research.

[53]  Kwang-Hyun Cho,et al.  Inferring Sequential Order of Somatic Mutations during Tumorgenesis based on Markov Chain Model , 2015, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[54]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[55]  Fei Liu,et al.  Constrained target controllability of complex networks , 2017 .

[56]  Jannik N. Andersen,et al.  Cancer genomics: from discovery science to personalized medicine , 2011, Nature Medicine.

[57]  Xiangtian Yu,et al.  Individual-specific edge-network analysis for disease prediction , 2017, Nucleic acids research.

[58]  A. Barabasi,et al.  Controllability analysis of the directed human protein interaction network identifies disease genes and drug targets , 2015, Proceedings of the National Academy of Sciences.

[59]  Rui Liu,et al.  Edge biomarkers for classification and prediction of phenotypes , 2014, Science China Life Sciences.

[60]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[61]  Benjamin J. Raphael,et al.  Pan-Cancer Network Analysis Identifies Combinations of Rare Somatic Mutations across Pathways and Protein Complexes , 2014, Nature Genetics.

[62]  R. Schilsky.  Personalized medicine in oncology: the future is now , 2010, Nature Reviews Drug Discovery.